1. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Issue 3 (March 2022) Authors: Thiery-Vuillemin, Antoine; de Bono, Johann; Hussain, Maha; Roubaud, Guilhem; Procopio, Giuseppe; Shore, Neal; Fizazi, Karim; dos Anjos, Gabriel; Gravis, Gwenaelle; Joung, Jae Young; Matsubara, Nobuaki; Castellano, Daniel; Degboe, Arnold; Gresty, Chris; Kang, Jinyu; Allen, Allison; Poehlein, Chris... Journal: Lancet oncology Issue: Volume 23:Issue 3(2022) Page Start: 393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗